Phase II trial of enzastaurin (Enz) with bevacizumab (BV) in adults with recurrent glioblstoma (GBM).

被引：1
|
作者：
Moustakas, A.
Iwamoto, F. M.
Kreisl, T. N.
Sul, J.
Kim, L. J.
Butman, J. A.
Albert, P. S.
Fine, H. A.
机构：
[1] NCI, Neurooncol Branch, NIH, Bethesda, MD 20892 USA
[2] Univ Massachusetts, Sch Med, Worcester, MA USA
[3] NIH, Bethesda, MD 20892 USA
[4] NCI, NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e12511
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12511
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PHASE II TRIAL OF ENZASTAURIN (ENZ) WITH BEVACIZUMAB (BV) IN ADULTS WITH RECURRENT GLIOBLASTOMA (GEM)
    Moustakas, Argirios
    Iwamoto, Fabio M.
    Kreisl, Teri N.
    Sul, Joohee
    Kim, Lyndon
    Butman, John
    Albert, Paul
    Fine, Howard A.
    NEURO-ONCOLOGY, 2010, 12 : 37 - 37
  • [2] Phase I study of enzastaurin (ENZ) and bevacizumab (BV) in patients with advanced cancer
    Resta, L. P.
    Ermisch, S.
    Collins, C.
    Nicol, S. J.
    Armstrong, D. K.
    Wang, T.
    Zhang, Z.
    Thornton, D.
    Carducci, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas
    Odia, Yazmin
    Iwamoto, Fabio M.
    Moustakas, Argirios
    Fraum, Tyler J.
    Salgado, Carlos A.
    Li, Aiguo
    Kreisl, Teri N.
    Sul, Joohee
    Butman, John A.
    Fine, Howard A.
    JOURNAL OF NEURO-ONCOLOGY, 2016, 127 (01) : 127 - 135
  • [4] A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas
    Yazmin Odia
    Fabio M. Iwamoto
    Argirios Moustakas
    Tyler J. Fraum
    Carlos A. Salgado
    Aiguo Li
    Teri N. Kreisl
    Joohee Sul
    John A. Butman
    Howard A. Fine
    Journal of Neuro-Oncology, 2016, 127 : 127 - 135
  • [5] Phase II trial of bevacizumab and erlotinib in recurrent glioblastoma multiforme (GBM)
    Sathornsumetee, Sith
    Vredenburgh, James
    Rich, Jeremy
    Desjardins, Annick
    Quinn, Jennifer
    Bota, Daniela
    Goli, Krishna
    Mathe, Alyssa
    Gururangan, Sridharan
    Friedman, Allan
    Friedman, Henry
    Reardon, David
    NEURO-ONCOLOGY, 2007, 9 (04) : 516 - 516
  • [6] ENZASTAURIN (ENZ) VERSUS LOMUSTINE (CCNU) IN THE TREATMENT OF RECURRENT, INTRACRANIAL GLIOBLASTOMA (GBM): A PHASE III STUDY
    Wick, W.
    Puduvalli, V. K.
    Chamberlain, M.
    Carpentier, A.
    Cher, L.
    Mason, W.
    Van den Bent, M.
    Hong, S.
    Thornton, D.
    Fine, H.
    NEURO-ONCOLOGY, 2008, 10 (06) : 1068 - 1068
  • [7] Phase I study of enzastaurin (ENZ) and bevacizumab (BV) in patients with advanced cancer: Safety, pharmacokinetics (PK), and response assessment
    Carducci, M. A.
    Armstrong, D. K.
    Collins, C.
    Wang, T.
    Schaefer, S.
    Ermisch, S.
    Musib, L. C.
    Nicol, S.
    Thornton, D. E.
    Zhang, Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] Enzastaurin (ENZ) versus lomustine (CCNU) in the treatment of recurrent, intracranial glioblastoma multiforme (GBM): A phase III study
    Fine, H. A.
    Puduvalli, V. K.
    Chamberlain, M. C.
    Carpentier, A. F.
    Cher, L.
    Mason, W. P.
    van den Bent, M. J.
    Hong, S.
    Thornton, D.
    Wick, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] PHASE 1 TRIAL OF BEVACIZUMAB PLUS TPI 287 IN ADULTS WITH RECURRENT GLIOBLASTOMA (GBM)
    Conrad, Charles
    Yung, W. K. Alfred
    deGroot, John
    Gilbert, Mark
    Loghin, Monica
    Penas-Prado, Marta
    Tremont, Ivo
    Silberman, Sandra
    Picker, Donald
    NEURO-ONCOLOGY, 2013, 15 : 106 - 106
  • [10] NCCTG phase II trail of bevacizumab in combination with sorafenib in recurrent GBM
    Galanis, E.
    Jaeckle, K. A.
    Anderson, S.
    Kaufmann, T. J.
    Uhm, J. H.
    Giannini, C.
    Kumar, S.
    Northfelt, D. W.
    Flynn, P. J.
    Buckner, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345